Oncotelic Unveils AI-Driven GMP Manufacturing Platform at BIO 2026 — Oncotelic Therapeutics, Inc.

Event summary

Oncotelic launched its AI-powered GMP manufacturing services platform at the BIO International Convention 2026 in San Diego.
The platform integrates AI, digital batch records, and intelligent robotics from partner TechForce Robotics.
Key features include electronic batch record management, AI-assisted documentation, and quality compliance support.
Oncotelic aims to target emerging biotech firms, CDMOs, and cell/gene therapy developers with the platform.
The company also highlighted progress on its Deciparticle nanomedicine platform, including the Phase 1b study of SAPU003.

The big picture

Oncotelic's launch of an AI-powered GMP manufacturing platform underscores the growing trend of digital transformation in biotech and pharmaceutical manufacturing. The integration of AI and robotics aims to streamline operations, enhance compliance, and accelerate commercialization—a strategic move that could position Oncotelic as a key player in modernizing GMP workflows. The broader industry is witnessing a shift towards intelligent automation, with Oncotelic's platform potentially setting a new standard for efficiency and scalability in drug manufacturing.

What we're watching

Market Adoption: How quickly emerging biotech firms and CDMOs will integrate Oncotelic's AI-driven platform into their GMP operations.
Technological Integration: Whether the collaboration with TechForce Robotics can sustain seamless integration of AI and robotics in GMP environments.
Competitive Positioning: The pace at which Oncotelic can differentiate itself in the crowded AI-enabled GMP manufacturing software market.